Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31695277 | 1.00 | ABCB1 (0.30) | ABCB1 | |
| SCHEMBL24630325 | 0.94 | — | — | |
| SCHEMBL24630222 | 0.94 | — | — | |
| SCHEMBL31695118 | 0.93 | LMNA (0.31) | — | |
| SCHEMBL27390994 | 0.92 | POLB (0.31) | — | |
| SCHEMBL29326715 | 0.92 | — | — | |
| SCHEMBL24630324 | 0.92 | NANP (0.35) | ABCB1 | |
| SCHEMBL27391585 | 0.88 | — | — | |
| SCHEMBL31225519 | 0.87 | NEU4 (0.32) | — | |
| SCHEMBL13949941 | 0.87 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4554622-A2 | AUTOANTIGENS ENGINEERED TO SUPPRESS AUTOIMMUNE RESPONSE | Osprey Biopharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025076427-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024015872-A2 | AUTOANTIGENS ENGINEERED TO SUPPRESS AUTOIMMUNE RESPONSE | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4274582-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | Osprey Biopharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | ABCB1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.